As MannKind is reaching the crest of the depicted hill and sunset, is it time for company executives and board members to consider the nine-year record seeking profitability on the back of the Afrezza revenue stream and the results achieved?

Source: https://seekingalpha.com/article/4654096-mannkind-continues-kick-can-down-road-for-investors?source=feed_all_articles

As we approach another pivotal point for MannKind I thought it might be good to review the history of MannKind, the key players, and critical events that were part of their history.

Source: https://seekingalpha.com/article/4578912-mannkind-the-continuing-saga-of-what-they-say-vs-what-they-do?source=feed_all_articles

As we approach another pivotal point for MannKind I thought it might be good to review the history of MannKind, the key players, and critical events that were part of their history.

Source: https://seekingalpha.com/article/4578912-mannkind-the-continuing-saga-of-what-they-say-vs-what-they-do?source=feed_all_articles

Cantor Fitzgerald raised their price target on MannKind from $6.50 to $7.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 8th.

Source: https://www.dailypolitical.com/2023/11/11/fy2025-eps-estimates-for-mannkind-co-nasdaqmnkd-reduced-by-hc-wainwright.html

What is unique about MannKind and United products is that each is a life-saving drug that must be dosed typically multiple times a day.

Source: https://seekingalpha.com/article/4654096-mannkind-continues-kick-can-down-road-for-investors?source=feed_all_articles